The platelet-derived growth factor receptor α is destabilized by geldanamycins in cancer cells

Daniela Matei, Minati Satpathy, Liyun Cao, Yi Chun Lai, Harikrishna Nakshatri, David B. Donner

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

The heat shock protein HSP90 serves as a chaperone for receptor protein kinases, steroid receptors, and other intracellular signaling molecules. Targeting HSP90 with ansamycin antibiotics disrupts the normal processing of clients of the HSP90 complex. The platelet-derived growth factor receptor α (PDGFRα) is a tyrosine kinase receptor up-regulated and activated in several malignancies. Here we show that the PDGFRα forms a complex with HSP90 and the co-chaperone cdc37 in ovarian, glioblastoma, and lung cancer cells. Treatment of cancer cell lines expressing the PDGFRα with the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) promotes degradationofthereceptor.Likewise,phospho-Akt, a downstream target, is degraded after treatment with 17-AAG. In contrast, PDGFRα expression is not affected by 17-AAG in normal human smooth muscle cells or 3T3 fibroblasts. PDGFRα degradation by 17-AAG is inhibited by the proteasome inhibitor MG132. High molecular weight, ubiquitinated forms of the receptor are detected in cells treated with 17-AAG and MG132. Degradation of the receptor is also inhibited by a specific neutralizing antibody to the PDGFRα but not by a neutralizing antibody to PDGF or by imatinib mesylate (Gleevec). Ultimately, PDGFRα-mediated cell proliferation is inhibited by 17-AAG. These results show that 17-AAG promotes PDGFRα degradation selectively in transformed cells. Thus, not only mutated tyrosine kinases but also overexpressed receptors in cancer cells can be targeted by 17-AAG.

Original languageEnglish (US)
Pages (from-to)445-453
Number of pages9
JournalJournal of Biological Chemistry
Volume282
Issue number1
DOIs
StatePublished - Jan 5 2007

Fingerprint

tanespimycin
Platelet-Derived Growth Factor Receptors
Cells
Neoplasms
Neutralizing Antibodies
Degradation
Rifabutin
HSP90 Heat-Shock Proteins
Proteasome Inhibitors
geldanamycin
Steroid Receptors
Cell proliferation
Receptor Protein-Tyrosine Kinases
Fibroblasts
Glioblastoma
Ovarian Neoplasms
Protein-Tyrosine Kinases
Protein Kinases
Smooth Muscle Myocytes
Muscle

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Cite this

The platelet-derived growth factor receptor α is destabilized by geldanamycins in cancer cells. / Matei, Daniela; Satpathy, Minati; Cao, Liyun; Lai, Yi Chun; Nakshatri, Harikrishna; Donner, David B.

In: Journal of Biological Chemistry, Vol. 282, No. 1, 05.01.2007, p. 445-453.

Research output: Contribution to journalArticle

Matei, Daniela ; Satpathy, Minati ; Cao, Liyun ; Lai, Yi Chun ; Nakshatri, Harikrishna ; Donner, David B. / The platelet-derived growth factor receptor α is destabilized by geldanamycins in cancer cells. In: Journal of Biological Chemistry. 2007 ; Vol. 282, No. 1. pp. 445-453.
@article{38e3f2ff394b42649a2e12626dde6e7c,
title = "The platelet-derived growth factor receptor α is destabilized by geldanamycins in cancer cells",
abstract = "The heat shock protein HSP90 serves as a chaperone for receptor protein kinases, steroid receptors, and other intracellular signaling molecules. Targeting HSP90 with ansamycin antibiotics disrupts the normal processing of clients of the HSP90 complex. The platelet-derived growth factor receptor α (PDGFRα) is a tyrosine kinase receptor up-regulated and activated in several malignancies. Here we show that the PDGFRα forms a complex with HSP90 and the co-chaperone cdc37 in ovarian, glioblastoma, and lung cancer cells. Treatment of cancer cell lines expressing the PDGFRα with the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) promotes degradationofthereceptor.Likewise,phospho-Akt, a downstream target, is degraded after treatment with 17-AAG. In contrast, PDGFRα expression is not affected by 17-AAG in normal human smooth muscle cells or 3T3 fibroblasts. PDGFRα degradation by 17-AAG is inhibited by the proteasome inhibitor MG132. High molecular weight, ubiquitinated forms of the receptor are detected in cells treated with 17-AAG and MG132. Degradation of the receptor is also inhibited by a specific neutralizing antibody to the PDGFRα but not by a neutralizing antibody to PDGF or by imatinib mesylate (Gleevec). Ultimately, PDGFRα-mediated cell proliferation is inhibited by 17-AAG. These results show that 17-AAG promotes PDGFRα degradation selectively in transformed cells. Thus, not only mutated tyrosine kinases but also overexpressed receptors in cancer cells can be targeted by 17-AAG.",
author = "Daniela Matei and Minati Satpathy and Liyun Cao and Lai, {Yi Chun} and Harikrishna Nakshatri and Donner, {David B.}",
year = "2007",
month = "1",
day = "5",
doi = "10.1074/jbc.M607012200",
language = "English (US)",
volume = "282",
pages = "445--453",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "1",

}

TY - JOUR

T1 - The platelet-derived growth factor receptor α is destabilized by geldanamycins in cancer cells

AU - Matei, Daniela

AU - Satpathy, Minati

AU - Cao, Liyun

AU - Lai, Yi Chun

AU - Nakshatri, Harikrishna

AU - Donner, David B.

PY - 2007/1/5

Y1 - 2007/1/5

N2 - The heat shock protein HSP90 serves as a chaperone for receptor protein kinases, steroid receptors, and other intracellular signaling molecules. Targeting HSP90 with ansamycin antibiotics disrupts the normal processing of clients of the HSP90 complex. The platelet-derived growth factor receptor α (PDGFRα) is a tyrosine kinase receptor up-regulated and activated in several malignancies. Here we show that the PDGFRα forms a complex with HSP90 and the co-chaperone cdc37 in ovarian, glioblastoma, and lung cancer cells. Treatment of cancer cell lines expressing the PDGFRα with the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) promotes degradationofthereceptor.Likewise,phospho-Akt, a downstream target, is degraded after treatment with 17-AAG. In contrast, PDGFRα expression is not affected by 17-AAG in normal human smooth muscle cells or 3T3 fibroblasts. PDGFRα degradation by 17-AAG is inhibited by the proteasome inhibitor MG132. High molecular weight, ubiquitinated forms of the receptor are detected in cells treated with 17-AAG and MG132. Degradation of the receptor is also inhibited by a specific neutralizing antibody to the PDGFRα but not by a neutralizing antibody to PDGF or by imatinib mesylate (Gleevec). Ultimately, PDGFRα-mediated cell proliferation is inhibited by 17-AAG. These results show that 17-AAG promotes PDGFRα degradation selectively in transformed cells. Thus, not only mutated tyrosine kinases but also overexpressed receptors in cancer cells can be targeted by 17-AAG.

AB - The heat shock protein HSP90 serves as a chaperone for receptor protein kinases, steroid receptors, and other intracellular signaling molecules. Targeting HSP90 with ansamycin antibiotics disrupts the normal processing of clients of the HSP90 complex. The platelet-derived growth factor receptor α (PDGFRα) is a tyrosine kinase receptor up-regulated and activated in several malignancies. Here we show that the PDGFRα forms a complex with HSP90 and the co-chaperone cdc37 in ovarian, glioblastoma, and lung cancer cells. Treatment of cancer cell lines expressing the PDGFRα with the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) promotes degradationofthereceptor.Likewise,phospho-Akt, a downstream target, is degraded after treatment with 17-AAG. In contrast, PDGFRα expression is not affected by 17-AAG in normal human smooth muscle cells or 3T3 fibroblasts. PDGFRα degradation by 17-AAG is inhibited by the proteasome inhibitor MG132. High molecular weight, ubiquitinated forms of the receptor are detected in cells treated with 17-AAG and MG132. Degradation of the receptor is also inhibited by a specific neutralizing antibody to the PDGFRα but not by a neutralizing antibody to PDGF or by imatinib mesylate (Gleevec). Ultimately, PDGFRα-mediated cell proliferation is inhibited by 17-AAG. These results show that 17-AAG promotes PDGFRα degradation selectively in transformed cells. Thus, not only mutated tyrosine kinases but also overexpressed receptors in cancer cells can be targeted by 17-AAG.

UR - http://www.scopus.com/inward/record.url?scp=33846982944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846982944&partnerID=8YFLogxK

U2 - 10.1074/jbc.M607012200

DO - 10.1074/jbc.M607012200

M3 - Article

C2 - 17079230

AN - SCOPUS:33846982944

VL - 282

SP - 445

EP - 453

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 1

ER -